Dr. Shimon Gross reports

DIAGNOSTEAR TECHNOLOGIES INC. ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS

Further to Diagnostear Technologies Inc.'s news release from June 3, 2025, to Oct. 24, 2025, the company has closed its non-brokered private placement of units, with each unit consisting of one common share in the capital of the company and one common share purchase warrant, in the principal amount of $925,000.

The company issued 1.85 million units at a price of 50 cents per unit in connection with the closing of the offering.

Each warrant will be exercisable to purchase one common share at an exercise price of $1 for a term of 18 months from the closing date of the offering, which will be May 18, 2027.

No finders' fees were paid in connection with this offering.

The net proceeds of the offering will be used for the company's working capital and general corporate purposes.

The offering is subject to the receipt of all required regulatory approval, including acceptance of the Canadian Securities Exchange. All securities issued in connection with the offering (including the shares and warrants) and the settlement are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.

About Diagnostear Technologies Inc.

Diagnostear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. Diagnostear's TeaRx technology is a diagnostic platform intended for rapid, point-of-care testing (POCT) of ophthalmic pathologies through multiparameter analysis of non-invasively collected tear fluid. The first CE-IVD, and Israeli MoH-approved, test based on the TeaRxplatform is intended for diagnosis of dry eye syndrome (DES TeaRx Dry Eye). This product is not cleared by the U.S. Food and Drug Administration (FDA) yet. Beyond DES, Diagnostear is developing innovative tests based on the TeaRx platform for additional ophthalmic indications. Among others, Diagnostear's pipeline includes TeaRx Red Eye: the first test of its kind for differential assessment of adenoviral conjunctivitis, herpetic keratitis and allergic conjunctivitis.

We seek Safe Harbor.